Regulatory
Oncology NDA accepted first cycle
Built the full submission strategy and FDA meeting package for a mid-size biotech, cutting review risk and saving nine months.
Veridian Pharma Consulting partners with biotech and pharmaceutical teams to accelerate approvals, de-risk clinical operations, and open payer pathways across the US and EU.
Book a Strategy CallSee Our WorkSenior-only teams covering the full journey from molecule to market, built on the practices used by leading pharmaceutical consultancies.
FDA and EMA pathway design, pre-submission meetings, briefing books, and lifecycle labeling strategy that shortens review cycles.
Payer evidence plans, HEOR dossiers, and launch pricing corridors that translate clinical value into reimbursement.
Protocol optimization, site network selection, and vendor oversight to keep trials on time and inspection-ready.
Filter recent engagements by specialty to see how we deliver measurable outcomes.
Built the full submission strategy and FDA meeting package for a mid-size biotech, cutting review risk and saving nine months.
Payer value dossier and pricing corridor for a rare-disease therapy achieved coverage across all five major EU markets.
Site network redesign across 12 countries lifted enrollment 60 percent and returned the trial to its original timeline.
Repositioned a biosimilar comparability package after initial pushback, securing positive CHMP scientific advice.
Pre-launch payer advisory boards and evidence gap analysis delivered day-one formulary access with three national payers.
Mock inspections and CAPA coaching prepared a sponsor for a successful FDA BIMO inspection with zero 483 findings.
Tell us about your program and a senior advisor will respond within one business day. Prefer email?
advisors@veridianpharma.example
Boston | Basel | London